Fracture risk associated with chronic use of bisphosphonates: evidence today

Author： Charopoulos Ioannis   Orme Steve   Giannoudis Peter V  

Publisher： Informa Healthcare

ISSN： 1474-0338

Source： Expert Opinion on Drug Safety, Vol.10, Iss.1, 2011-01, pp. : 67-76

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Chronic diuretic use associated with increased mortality risk in HF

By  

Inpharma, Vol. 1, Iss. 1552, 2006-01 ,pp. : 20-20

Adis International

Access to resources Recommend Favorite

5-α-reductase inhibitor use does not appear to be associated with an increased risk of hip fracture

By  

Inpharma, Vol. 1, Iss. 1660, 2008-01 ,pp. : 17-17

Adis International

Access to resources Recommend Favorite

Amgen Canada Inc. is warning of the risk of atypical femoral fracture associated with use of the osteoporosis treatment, Prolia [denosumab].

By  

Reactions Weekly, Vol. 1, Iss. 1430, 2012-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite

Evidence mounts regarding PPIs and fracture risk

By  

Reactions Weekly, Vol. 1, Iss. 1325, 2010-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

Bisphosphonates NOT associated with atrial fibrillation

By  

Reactions Weekly, Vol. 1, Iss. 1194-1195, 2008-01 ,pp. : 1-1

Adis International

Access to resources Recommend Favorite